Laura Sourd
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Sourd has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Elisabetta Marangoni
Translational Research Department, Institut Curie
82 shared publications - Chao Hu
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, China
36 shared publications - Di Wu
Department of Medicinal Chemistry, Pharmacology, Project Management, Drug Metabolism and Pharmacokinetics, TransThera Sciences (Nanjing), Inc., Nanjing, Jiangsu, P.R. China
36 shared publications - Dong Wang
School of Basic Medical Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China
36 shared publications - Frank Wu
TransThera Sciences (Nanjing), Inc., Nanjing, China
36 shared publications - Guoyu Li
Department of Medicinal Chemistry, Pharmacology, Project Management, Drug Metabolism and Pharmacokinetics, TransThera Sciences (Nanjing), Inc., Nanjing, Jiangsu, P.R. China
36 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF13
PLK1 Inhibition by Onvansertib Enhances Paclitaxel Efficacy and Overcomes Resistance in HR+/HER2− Breast Cancer Refractory to Endocrine Therapy and CDK4/6 Inhibitors
Hormone receptor (HR)–positive/HER2− metastatic breast cancer (mBC) that progresses on cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) faces a major therapeutic challenge, and chemotherapy is frequently used despite its modest clinical benefit. Paclitaxel is commonly used in this setting; however, intrinsic and acquired resistance substantially limits the depth and durability of response. Polo-like kinase 1 (PLK1) is a key mitotic regulator implicated in resistance to taxanes and ET/CDK4/6i. We evaluated whether PLK1 inhibition with onvansertib enhances paclitaxel activity in HR+ breast cancer models with intrinsic or acquired ET/CDK4/6i resistance, testing across six cell lines and eight patient-derived xenograft (PDX) models, including paclitaxel-resistant tumors. The combination synergistically inhibited cell viability in vitro and improved antitumor efficacy in xenograft models. Notably, the combination induced tumor regression across all paclitaxel-resistant models, with complete responses in more than half of treated animals in three of five models, and deep, durable regressions in paclitaxel-sensitive models, markedly outperforming either agent alone. Mechanistically, the combination exacerbated mitotic stress, disrupted spindle architecture, suppressed proliferative and cell cycle–associated transcriptional programs, and promoted proteasome-dependent c-MYC degradation, resulting in enhanced apoptotic cell death in vitro and in vivo. Importantly, genetic modulation of c-MYC expression altered the apoptotic response, establishing c-MYC downregulation as a key mediator of the observed antitumor efficacy. Collectively, these findings support PLK1 inhibition as a mechanistically rational strategy to potentiate taxane efficacy and overcome resistance in advanced HR+/HER2− breast cancer.
- 2 November 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF13
Open AccessPLK1 Inhibition by Onvansertib Enhances Paclitaxel Efficacy and Overcomes Resistance in HR+/HER2− Breast Cancer Refractory to Endocrine Therapy and CDK4/6 Inhibitors
Hormone receptor (HR)–positive/HER2− metastatic breast cancer (mBC) that progresses on cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET) faces a major therapeutic challenge, and chemotherapy is frequently used despite its modest clinical benefit. Paclitaxel is commonly used in this setting; however, intrinsic and acquired resistance substantially limits the depth and durability of response. Polo-like kinase 1 (PLK1) is a key mitotic regulator implicated in resistance to taxanes and ET/CDK4/6i. We evaluated whether PLK1 inhibition with onvansertib enhances paclitaxel activity in HR+ breast cancer models with intrinsic or acquired ET/CDK4/6i resistance, testing across six cell lines and eight patient-derived xenograft (PDX) models, including paclitaxel-resistant tumors. The combination synergistically inhibited cell viability in vitro and improved antitumor efficacy in xenograft models. Notably, the combination induced tumor regression across all paclitaxel-resistant models, with complete responses in more than half of treated animals in three of five models, and deep, durable regressions in paclitaxel-sensitive models, markedly outperforming either agent alone. Mechanistically, the combination exacerbated mitotic stress, disrupted spindle architecture, suppressed proliferative and cell cycle–associated transcriptional programs, and promoted proteasome-dependent c-MYC degradation, resulting in enhanced apoptotic cell death in vitro and in vivo. Importantly, genetic modulation of c-MYC expression altered the apoptotic response, establishing c-MYC downregulation as a key mediator of the observed antitumor efficacy. Collectively, these findings support PLK1 inhibition as a mechanistically rational strategy to potentiate taxane efficacy and overcome resistance in advanced HR+/HER2− breast cancer.
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Characterization of the persister state commonalities in vivo
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Characterization of the persister state commonalities in vivo
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Expression of transcription factors predicted to regulate activation of the persister expression program in vivo
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Expression of transcription factors predicted to regulate activation of the persister expression program in vivo
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Integrative functional analysis complementary to that described in the main Figure 3, showing that ACSL4 targeting prevents ferroptosis execution in MCF7 Y537C and T47D Y537C cells
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Integrative functional analysis complementary to that described in the main Figure 3, showing that ACSL4 targeting prevents ferroptosis execution in MCF7 Y537C and T47D Y537C cells
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Identification of FOSL1 as a key regulator of the persister expression program in vitro
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Identification of FOSL1 as a key regulator of the persister expression program in vitro
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Data from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)–positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4), which plays a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. Although ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective ER degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction.Significance:ESR1 mutations in breast cancer induce metabolic changes that trigger ferroptosis sensitivity, enabling ferroptosis inducers to enhance selective ER degraders' efficacy and positioning ACSL4 as a biomarker for guiding therapy in endocrine-resistant disease.
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from ESR1-Activating Mutations Confer Metabolic Vulnerabilities in ER+ Breast Cancer
Endocrine therapy (ET) is the standard of care for estrogen receptor (ER)–positive breast cancer. Point mutations in the ligand-binding domain of the gene encoding the estrogen receptor (ESR1) are rare in naïve ER+ breast cancer while becoming common in the ET-resistant setting. In this study, we found that ESR1 mutations expose breast cancers to critical vulnerabilities related to lipid metabolism. Particularly, ESR1 mutations that induce constitutive ER activation drove aberrant lipid biogenesis and lipid upload in parallel with increased expression of acyl-CoA synthetase long-chain family member 4 (ACSL4), which plays a crucial role in fatty acid activation and has been shown to correlate with increased ferroptosis susceptibility. Although ER+ breast cancer cells displayed ferroptosis resistance, the presence of ESR1 mutations rendered tumor cells sensitive to ferroptosis induction. Importantly, ferroptosis inducers potentiated the effects of the selective ER degraders fulvestrant and elacestrant, which are the standard of care for breast cancers carrying ESR1 mutations. These findings, validated both in preclinical models and in patient-derived material, identify a combinatory therapeutic approach in the setting of ET resistance and establish ACSL4 as an important biomarker to recognize ER+ breast cancers susceptible to ferroptosis induction.Significance:ESR1 mutations in breast cancer induce metabolic changes that trigger ferroptosis sensitivity, enabling ferroptosis inducers to enhance selective ER degraders' efficacy and positioning ACSL4 as a biomarker for guiding therapy in endocrine-resistant disease.